Review: The use of proteomics as a research methodology for studying cancer-related fatigue: a review

Abstract

There is an increasing emphasis on using translational research to examine mechanisms and increase our understanding of disease. Translational research involves the use of basic science techniques to generate new treatments for use in a clinical setting — the so called ‘bench to bedside’ approach. This methodology could be used to enhance our understanding of complex symptoms such as cancer-related fatigue. This review will examine specifically the potential role of the science of protein structure and function (proteomics) as a technique to improve our knowledge in this area. This will include an explanation of the specific methods used in this research in order to increase our understanding of the mechanisms of cancer-related fatigue and discuss potential directions for future research with the development of more targeted therapies.

Keywords

proteomics cancer-related fatigue research design biological specimen banks

Get full access to this article

View all access options for this article.

References

Andrews PLR , Morrow GR , Hickok JT , et al. Mechanisms and models of fatigue associated with cancer and its treatment: Evidence of pre-clinical and clinical studies. In: Armes J , Krishnasamy M , Higginson I (eds) Fatigue in cancer. Oxford: OUP, 2004, p.51-87.

Stone P. , Richards M. , A’ Hern R. , et al. Fatigue in patients with cancers of the breast or prostate undergoing radical radiotherapy. J Pain Symptom Manage 2001; 22: 1007-1015.

Stone P. , Hardy J. , Broadley K. , et al. Fatigue in advanced cancer: a prospective controlled cross-sectional study. Br J Cancer 1999; 79: 1479-1486.

Minton O. , Stone P. How common is fatigue in disease-free breast cancer survivors? A systematic review of the literature. Breast Cancer Res Treat 2008; 112: 5-13.

Minton O. , Stone P. , Richardson A. , et al. Drug therapy for the management of cancer related fatigue. Cochrane Database Syst Rev 2008; CD006704.

Cramp F. , Daniel J. Exercise for the management of cancer-related fatigue in adults. Cochrane Database Syst Rev 2008; Issue 2. Chichester, UK: John Wiley & Sons Ltd. DOI: 10.1002/14651858.CD006145.pub2.

Goedendorp M. , Gielissen M. , Verhagen C. , et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009; Issue 1. DOI: 10.1002/14651858.CD006953.pub2.

Bohlius J. , Schmidlin K. , Brillant C. , et al. Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials. Lancet 2009; 373: 1532-1542.

Prue G. , Rankin J. , Allen J. , et al. Cancer-related fatigue: A critical appraisal. Eur J Cancer 2006; 42: 846-863.

10.

Minton O. , Stone P. A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 2009; 20: 17-25.

11.

Cella D. The Functional Assessment of Cancer Therapy-Anemia (FACT-An) Scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin Hematol 1997; 34: 13-19.

12.

Chalder T. , Berelowitz G. , Pawlikowska T. , et al. Development of a fatigue scale. J Psychosom Res 1993; 37: 147-153.

13.

Aaronson NK , Ahmedzai S. , Bergman B. , et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85: 365-376.

14.

Bower JE , Ganz PA , Desmond KA , et al. Fatigue in breast cancer survivors: occurrence, correlates, and impact on quality of life. J Clin Oncol 2000; 18: 743-753.

15.

Cella D. , Peterman A. , Passik S. , et al. Progress toward guidelines for the management of fatigue. Oncology (Huntington) 1998 ; 12: 369-377.

16.

Spitzer M. , Gibbon Miriam R. , Williams J. Structured Clinical Interview for DSM-IV-TR Axis I Disorders, Research Version, Non-patient Edition. (SCID-I/NP). New York: New York State Psychiatric Institute, 2002 .

17.

Zigmond AS , Snaith RP The hospital anxiety and depression scale. Acta Psychiatr Scand 1983; 67: 361-370.

18.

Murphy H. , Alexander S. , Stone P. , et al. Investigation of diagnostic criteria for cancer-related fatigue syndrome in patients with advanced cancer: a feasibility study. Palliat Med 2006; 20: 413-418.

19.

Seruga B. , Zhang H. , Bernstein LJ , et al. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer 2008; 8: 887-899.

20.

Schubert C. , Hong S. , Natarajan L. , et al. The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain Behav Immun 2007; 21: 413-427.

21.

Rich T. , Innominato PF , Boerner J. , et al. Elevated serum cytokines correlated with altered behavior, serum cortisol rhythm, and dampened 24-hour rest-activity patterns in patients with metastatic colorectal cancer. Clin Cancer Res 2005; 11: 1757-1764.

22.

Villar-Garea A. , Griese M. , Imhof A. Biomarker discovery from body fluids using mass spectrometry. J Chromatog B 2007; 849: 105-114.

23.

Kim M. -R, Kim C. -W. Human blood plasma preparation for two-dimensional gel electrophoresis . J Chromatog B 2007; 849: 203-210.

24.

Skorpen F. , Laugsand EA , Klepstad P. , et al. Variable response to opioid treatment: any genetic predictors within sight? Palliat Med 2008; 22: 310-327.

25.

Dass C. Fundamentals of contemporary mass spectrometry. Hoboken NJ: John Wiley and Sons, 2007, p.3-13.

26.

Landmark-Hoyvik H. , Reinertsen KV , Loge JH , et al. Alterations of gene expression in blood cells associated with chronic fatigue in breast cancer survivors. Pharmacogenomics J 2009 ; https://dx-doi-org.web.bisu.edu.cn/10.1038/tpj.2009.27.

27.

Pan W. A comparative review of statistical methods for discovering differentially expressed genes in replicated microarray experiments. Bioinformatics 2002; 18: 546-554.

28.

Rai A. , Gelfand GA , Haywood B. , et al. HUPO Plasma Proteome Project specimen collection and handling: Towards the standardization of parameters for plasma proteome samples. Proteomics 2005; 5: 3262-3277.

29.

Pusztai L. , Mendoza TR , Reuben JM , et al. Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine 2004; 25: 94-102.

30.

Geinitz H. , Zimmermann FB , Stoll P. , et al. Fatigue, serum cytokine levels, and blood cell counts during radiotherapy of patients with breast cancer. Int J Radiat Oncol Biol Phys 2001; 51: 691-698.

31.

Wratten C. , Kilmurray J. , Nash S. , et al. Fatigue during breast radiotherapy and its relationship to biological factors. Int J Radiat Oncol Biol Phys 2004 ; 59: 160-167.

32.

Monk JP , Phillips G. , Waite R. , et al. Assessment of tumor necrosis factor alpha blockade as an intervention to improve tolerability of dose-intensive chemotherapy in cancer patients . J Clin Oncol 2006; 24: 1852-1859.

33.

Bower JE , Ganz PA , Aziz N. , et al. Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosom Med 2002; 64: 604-611.

34.

Stewart A. , Bielajew C. , Collins B. , et al. A meta-analysis of the neuropsychological effects of adjuvant chemotherapy treatment in women treated for breast cancer. Clin Neuropsychol 2006; 20: 76-89.

35.

Todorov P. , Cariuk P. , McDevitt T. , et al. Characterization of a cancer cachectic factor. Nature 1996; 379: 739-742.

36.

Eley HL , Skipworth RJE , Deans DAC , et al. Increased expression of phosphorylated forms of RNA-dependent protein kinase and eukaryotic initiation factor 2 alpha may signal skeletal muscle atrophy in weight-losing cancer patients. Br J Cancer 2008; 98: 443-449.

37.

EPCRC. European palliative care research collaborative - updates on work packages. http://www.epcrc.org/project_info.php (accessed 1 December 2009).